Second IND approved

In Feb., CS060304 FDA IND (NASH) approved

Clinical phase II launch

In Jan., CS0159 FDA Fast Track (NASH) approved
In Mar., won the title of "specialized and special new" small and medium-sized enterprise in Shanghai
In Jul., pre-A++ round of financing was completed

Clinical Phase I completed

In Sep., completed clinical phase I administration in U.S.

In Nov., CS060304 IND enabling

In Dec., CS0159 FDA IND (NASH) approved

In Dec., pre-A++ round of financing

First IND approved

In Sept., CS0159 FDA ODD (PSC) approved

In Oct., CS0159 FDA IND (PSC) approved

In Dec., CS0159 complete the first subject administration in U.S.

In Dec., pre-A+ round of financing was completed

IND & Pre-A round of financing succeeded

In Jul., CS0159 IND enabling

In Aug., Completion of equity structure adjustment & Establishment of ESOP platform

In Oct., pre-A round of financing was completed

Relocate

In Apr., Zhoupu site was put into operation

In May, Animal facilities were approved for operation

In Jul., Angel round financing was completed

Start-up

In Mar., Kangqiao East Road site started operation

In Aug., received a seed round investment

Establishment

In Dec., Cascade was established